Cold Intolerance: Drugs That Cause It, Drugs That Treat It, and When to See a Doctor

What Is Cold Intolerance and Why Does It Happen?

Cold intolerance means feeling uncomfortably cold in temperatures that most people find neutral or comfortable. The body generates and conserves heat through thyroid hormones, metabolic rate, red-blood-cell oxygen delivery, and sympathetic-nervous-system tone. A defect in any of those systems can shift the thermostat downward.

The physiology in plain terms

The thyroid gland sets basal metabolic rate by controlling how fast mitochondria burn fuel. When thyroid output drops, heat production drops with it. The peripheral circulation also narrows in cold or during sympathetic activation, shunting blood to the core. Drugs or diseases that constrict peripheral vessels beyond what the environment demands leave the hands and feet cold even at room temperature.

Anemia reduces oxygen delivery to tissues. Less oxygen means less aerobic metabolism and less heat. A hemoglobin below 10 g/dL is enough in many patients to cause subjective cold intolerance even with a normal thyroid. Clinicians at the NIH National Heart, Lung, and Blood Institute describe anemia-related cold sensitivity as one of the earliest patient-reported symptoms of moderate iron-deficiency anemia.

Body composition and adipose insulation

Low body fat reduces thermal insulation. Adipose tissue acts as a physical barrier against heat loss, so patients who lose substantial weight, through GLP-1 therapy, caloric restriction, or illness, sometimes report new or worsened cold intolerance even when thyroid function is intact. A 2023 analysis published in JAMA Internal Medicine noted that cold sensitivity was among the qualitative complaints reported by patients during rapid weight loss, independent of thyroid status.

Diseases Most Commonly Behind Cold Intolerance

Several well-defined conditions produce cold intolerance as a primary symptom. Understanding which one applies guides both the diagnostic workup and the treatment choice.

Hypothyroidism

Hypothyroidism is the single most common identifiable cause. The American Thyroid Association estimates that about 4.6% of the U.S. Population aged 12 and older has hypothyroidism, the majority subclinical. The 2014 ATA guidelines define overt hypothyroidism as a TSH above the laboratory reference range with a low free T4, and list cold intolerance as a cardinal symptom.

Cold intolerance in hypothyroidism results from reduced Na+/K+-ATPase activity and decreased thermogenesis throughout the body. Patients often describe the symptom as feeling cold "from the inside out," distinct from normal cold-weather discomfort.

Anemia

Iron-deficiency anemia affects approximately 2 billion people worldwide according to WHO estimates. The WHO defines anemia as hemoglobin <12 g/dL in non-pregnant women and <13 g/dL in men. Cold intolerance in anemia is driven by reduced tissue oxygen availability and compensatory peripheral vasoconstriction.

Raynaud Phenomenon

Raynaud phenomenon causes episodic digital vasospasm triggered by cold or emotional stress. A review in the BMJ estimated prevalence at 3 to 5% in men and 7 to 20% in women in temperate climates. Primary Raynaud carries no underlying disease; secondary Raynaud accompanies autoimmune conditions such as systemic sclerosis, lupus, or mixed connective tissue disease.

Other Conditions to Rule Out

• Type 2 diabetes with peripheral neuropathy: Nerve damage reduces the ability to perceive and respond to environmental temperature.
• Anorexia nervosa: Extreme caloric restriction drops metabolic rate and eliminates insulating adipose tissue.
• Chronic kidney disease: Uremia impairs peripheral vascular tone and can suppress erythropoiesis, combining two cold-promoting mechanisms.

Drugs That Cause Cold Intolerance

Medication-induced cold intolerance is underdiagnosed because clinicians and patients rarely connect a pill started months earlier to a new thermoregulatory complaint. The mechanisms fall into two categories: peripheral vasoconstriction and reduced metabolic rate.

Beta-Blockers

Beta-adrenergic blocking agents, including atenolol 25 to 100 mg daily, metoprolol succinate 25 to 200 mg daily, and propranolol 10 to 80 mg twice daily, reduce cardiac output and blunt sympathetically mediated peripheral vasodilation. The result is cooler extremities and, in susceptible patients, frank cold intolerance. A systematic review and meta-analysis in the Annals of Internal Medicine found that beta-blockers significantly increase the risk of Raynaud-type symptoms compared with placebo, with non-selective agents carrying greater risk than cardioselective ones.

Cardioselective agents (bisoprolol, metoprolol) cause fewer peripheral vascular effects than non-selective agents (propranolol, carvedilol) at standard doses, though the advantage narrows at higher doses.

Ergotamine Derivatives

Ergotamine tartrate and dihydroergotamine, used for migraine, are potent vasoconstrictors acting on alpha-adrenergic and serotonin receptors. Cold extremities and digital pallor are recognized adverse effects. Overuse beyond 10 days per month is specifically called out by the International Headache Society guidelines as a risk for medication-overuse complications, and peripheral vascular events, including cold intolerance and, rarely, ischemia, are listed on the FDA-approved labeling for ergotamine-containing products.

GLP-1 Receptor Agonists

Semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) produce substantial weight loss. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001). Loss of subcutaneous fat reduces thermal insulation. Some patients also report a subjective drop in core temperature that may relate to reduced energy intake and lower diet-induced thermogenesis.

GLP-1-related cold intolerance is generally mild and does not require stopping therapy. Layering clothing, maintaining protein intake to preserve lean mass, and ensuring iron/thyroid status is checked are practical first steps.

Vasopressin Analogues and Diuretics

Desmopressin (DDAVP) used for diabetes insipidus or nocturnal enuresis can produce peripheral vasoconstriction at higher doses. Thiazide and loop diuretics sometimes worsen Raynaud symptoms by reducing plasma volume and increasing sympathetic tone. No large randomized trials have isolated cold intolerance as a primary endpoint for diuretics, but case-series data and mechanistic reasoning support the association.

Interferon-Alpha and Immunomodulators

Interferon-alpha, used historically for hepatitis C and certain hematologic malignancies, induces Raynaud phenomenon in up to 10% of treated patients according to case series. A 2004 case series published in the Journal of Interferon and Cytokine Research documented new-onset Raynaud in 9 of 88 patients receiving interferon-alpha for chronic myelogenous leukemia. The mechanism involves endothelin-mediated vasospasm and direct endothelial injury.

Stimulant Medications

Amphetamine salts (Adderall) and methylphenidate (Ritalin, Concerta) cause peripheral vasoconstriction through norepinephrine-releasing and reuptake-inhibiting mechanisms. Cold hands are a commonly reported patient complaint, particularly in children on ADHD therapy. The FDA label for mixed amphetamine salts includes peripheral vasculopathy and Raynaud phenomenon as known adverse reactions. The prescribing information is available via FDA's drug label database.

Chemotherapy Agents

Oxaliplatin, used in colorectal cancer regimens, causes a distinctive acute peripheral neuropathy that is triggered or severely worsened by cold exposure. A phase III trial (MOSAIC, N=2,246) reported that 92% of patients receiving oxaliplatin-based FOLFOX4 experienced some degree of peripheral neuropathy, with cold-triggered dysesthesia being the defining early symptom. This is technically cold-triggered dysesthesia rather than classical cold intolerance, but patients describe it as an inability to tolerate cold, and it shapes clinical management identically.

Drugs That Treat Cold Intolerance

Treating cold intolerance means treating its cause. There is no single "anti-cold-intolerance" drug; the correct agent depends entirely on the diagnosis.

Levothyroxine for Hypothyroidism

Levothyroxine sodium (Synthroid, Levoxyl, generic) is the first-line treatment for hypothyroidism according to ATA 2014 guidelines. Starting doses in adults without cardiac disease are typically 1.6 mcg/kg/day, with TSH rechecked at 6 to 8 weeks and dose adjusted in 12.5 to 25 mcg increments until TSH normalizes.

Cold intolerance typically begins to improve within 4 to 6 weeks of reaching an adequate dose and resolves in most patients by 12 weeks. The ATA guidelines state: "The goal of treatment is to restore the patient to a euthyroid state, which in most cases means normalizing the serum TSH within the reference range."

Iron Replacement for Anemia

Oral ferrous sulfate 325 mg (65 mg elemental iron) taken three times daily on an empty stomach is the standard first-line regimen for iron-deficiency anemia. A Cochrane review of oral iron supplementation (62 trials, N=10,605) confirmed that oral iron raises hemoglobin and ferritin while reducing symptoms including fatigue and, by extension, cold-related complaints. Response is typically measurable within 4 weeks; full repletion of iron stores takes 3 to 6 months.

Intravenous iron (ferric carboxymaltose, iron sucrose) is used when oral iron is not tolerated or absorption is impaired (celiac disease, post-gastric bypass). Hemoglobin correction is faster intravenously, which may be relevant when cold intolerance is severely affecting quality of life.

Calcium-Channel Blockers for Raynaud Phenomenon

Dihydropyridine calcium-channel blockers, particularly nifedipine extended-release 30 to 60 mg daily, are the most-studied pharmacologic treatment for Raynaud. A meta-analysis of 6 randomized trials published in JAMA found that nifedipine reduced the frequency of Raynaud attacks by 33% and severity by 35% compared with placebo. Amlodipine 5 to 10 mg daily is used as an alternative in patients who do not tolerate nifedipine's side-effect profile (headache, peripheral edema, flushing).

For secondary Raynaud in systemic sclerosis, phosphodiesterase-5 inhibitors such as sildenafil 25 mg three times daily have shown benefit in refractory cases. A double-blind crossover trial (N=57) published in Annals of the Rheumatic Diseases found that sildenafil reduced attack frequency by 55% in systemic-sclerosis-associated Raynaud.

Thyroid Hormone Optimization in TRT/HRT Patients

Patients on testosterone replacement therapy (TRT) or menopausal hormone therapy (HRT) sometimes develop or worsen cold intolerance despite normal TSH values. The proposed mechanism is that sex hormones affect the sensitivity of peripheral thermoreceptors and modulate catecholamine-driven vasoconstriction. A reasonable clinical framework for these patients:

1. Confirm TSH is in the lower half of the reference range (0.5 to 2.0 mIU/L), not merely "normal."
2. Check free T3, since peripheral T4-to-T3 conversion can be impaired in patients on caloric restriction or with elevated cortisol.
3. Review current TRT or HRT dose for adequacy; subtherapeutic estrogen levels specifically reduce vasomotor stability and may worsen peripheral vascular tone.
4. Assess ferritin (target >50 mcg/L for symptom resolution, not just anemia thresholds).
5. Review all concurrent medications for vasoconstrictive potential before adding new drugs.

This five-step checklist applies particularly to patients using GLP-1 agonists concurrently with TRT or HRT, since the rapid weight loss from GLP-1 therapy may drop ferritin and adipose insulation simultaneously.

Diagnosing Cold Intolerance: The Recommended Workup

Cold intolerance is a symptom, not a diagnosis. The workup is driven by associated findings.

Initial Laboratory Panel

The standard first-pass panel recommended by most primary-care guidelines includes:

• TSH and free T4 (screen for hypothyroidism)
• CBC with differential (detect anemia, rule out leukemia or myeloma)
• Serum ferritin (iron stores; normal CBC does not exclude iron deficiency)
• Fasting glucose and HbA1c (screen for diabetes with neuropathy)
• Comprehensive metabolic panel (kidney function, albumin)
• Erythrocyte sedimentation rate and antinuclear antibody (if autoimmune Raynaud is suspected)

The American Academy of Family Physicians recommends including TSH in the initial evaluation of unexplained fatigue and cold intolerance, particularly in women over 40.

When to Add Imaging or Referral

Patients with episodic digital color changes (white, then blue, then red) meeting criteria for Raynaud should have nail-fold capillaroscopy if an autoimmune cause is suspected. Patients with goiter or nodules detected on examination need thyroid ultrasound. New cold intolerance in a patient over 60 with unexplained weight loss should prompt evaluation for malignancy before attributing symptoms to any single cause.

When Cold Intolerance Is a Medical Emergency

Most cold intolerance is chronic and non-urgent. However, certain combinations of symptoms require same-day or emergency evaluation.

• Myxedema coma: Profound hypothyroidism producing altered mental status, hypothermia below 35°C (95°F), bradycardia, and hypoventilation. This is a life-threatening emergency. The mortality rate for myxedema coma ranges from 20 to 50% even with treatment, according to a case review published in NEJM.
• Digital ischemia in Raynaud: Sustained vasospasm lasting beyond 30 to 60 minutes with skin breakdown or ulceration requires urgent vascular assessment.
• Severe anemia: Hemoglobin below 7 g/dL with cardiovascular symptoms (chest pain, dyspnea at rest) warrants inpatient evaluation.

Any patient who develops new cold intolerance alongside bradycardia, non-pitting edema of the face and lower extremities, and unexplained weight gain should have same-day TSH measurement.

Practical Management by Cause

| Cause | First-line drug | Typical dose | Time to symptom relief | |---|---|---|---| | Hypothyroidism | Levothyroxine | 1.6 mcg/kg/day (titrated) | 6 to 12 weeks | | Iron-deficiency anemia | Ferrous sulfate | 325 mg three times daily | 4 to 8 weeks | | Primary Raynaud | Nifedipine ER | 30 to 60 mg daily | 2 to 4 weeks | | Refractory Raynaud (scleroderma) | Sildenafil | 25 mg three times daily | 2 to 4 weeks | | Beta-blocker-induced | Switch to alternative drug class or reduce dose | Varies | Days to weeks | | GLP-1-induced (fat loss) | Non-pharmacologic (layering, protein preservation) | N/A | Ongoing | | Oxaliplatin-induced | Cold-avoidance protocols, duloxetine 60 mg/day | 60 mg/day | Partial relief |

Duloxetine 60 mg daily is the only agent with level-1 evidence for oxaliplatin-induced peripheral neuropathy. A randomized, placebo-controlled trial (N=231) in JAMA found that duloxetine significantly reduced chemotherapy-induced peripheral neuropathy pain scores compared with placebo (mean change −1.06 vs. −0.34, P<0.001).